Kane Biotech is pleased to announce that the Company has signed a non-exclusive licensing agreement with Avmor Ltd for the manufacturing, distribution and sales of the Company’s KBI Antibacterial Hard Surface Disinfectant (KBI) for the Canadian market.
One of the biggest and most active angel investor group in Canada is going to start to get busy in Winnipeg.
Rx&D released three reports that demonstrate the benefits of new medicines in Canada and the contribution of the innovative pharmaceutical industry to our health system and economy.
The provincial government has provided $30,000 towards program development through the Technical Vocational Initiative and Allan announced $50,000 in new funding to purchase equipment for the current school year.
Every business person in Winnipeg did not attend Centrallia events last week. And some of those who weren't there probably wished they were for all sorts of different reasons.
RIVA has safely and accurately prepared more than 1 million medication doses globally since its introduction in 2008. The milestone is especially notable in light of the recent outbreak of meningitis linked to contaminated pharmacy products.
This national honour identifies employers that lead their industries in offering exceptional workplaces for their employees.
Kane announced the issuance of a patent entitled “Compositions and Methods for Enzymatic Detachment of Bacterial and Fungal Biofilms”
Miraculins Inc. a medical diagnostic company focused on acquiring, developing and commercializing diagnostic tests and risk assessment technologies for unmet clinical needs; London Drugs, one of Canada’s leading pharmacy chains; and Pear Healthcare Soluti
UWinnipeg and Canadian Light Source join forces in new research collaboration
Kane has successfully developed the manufacturing process and completed the pilot scale production of the Company’s StrixNB Pet Oral Care product
Rx&D welcomed Health Canada's announcement that it is developing a regulatory framework surrounding medicines for rare diseases.
The province is adding 120 drugs to pharmacare, giving Manitobans greater choice and easing the burden of drug costs for patients and families
Three Winnipeg companies in various stages of development have just made different sorts of breakthroughs to allow their technologies greater access to markets
Kane announced that a Cooperative Research and Development Agreement has just been signed with the US Army Institute of Surgical Research
Medicure announced the development of a transdermal delivery formulation of its lead drug, AGGRASTAT(R). The ability to administer a drug transdermally (i.e. through the skin) provides a convenient way to deliver a stable, therapeutic level of medication
Three University of Manitoba doctors have been honoured for their pioneering efforts in caring for people with diabetes, heart failure and organ rejection.
Faculty of medicine doctors Heather Dean, Lorrie Kirshenbaum, and Peter Nickerson were inducted
Kane Biotech Inc. (TSX-V:KNE), a biotechnology company engaged in the development and commercialization of products that prevent and remove microbial biofilms announces veterinary clinic testing of the company’s StrixNB pet oral care product is underway.
Cangene Corporation (Cangene) today announces that its wholly owned subsidiary, Cangene Plasma Resources, Inc. has entered into an agreement for the sale of its three U.S. based plasma centres to Grifols, through wholly owned Grifols subsidiary, Biomat US
Canada’s largest publicly traded drug company is about to get a whole lot bigger, thanks to zit cream and aging faces.
Increasing Utilization of Food Processing Side Streams Key to Improving Health and Sustaining Production
September 13, 2012- Winnipeg, Manitoba- Manitoba researchers are meeting this week in…
Sign up for one of BAM's newsletter to learn more about bioscience, happenings in Manitoba's bioeconomy, industry conferences, and BAM training events.